J Korean Med Sci.  2012 Sep;27(9):1009-1013. 10.3346/jkms.2012.27.9.1009.

Subpopulations of Regulatory T Cells in Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Behcet's Disease

Affiliations
  • 1Department of Laboratory Medicine, Keimyung University School of Medicine, Daegu, Korea. ksksmom@dsmc.or.kr
  • 2Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.

Abstract

Recently, subpopulations of regulatory T (Treg) cells, resting Treg (rTreg) and activated Treg (aTreg), have been discovered. The authors investigated the relationship between the change of Treg, aTreg and rTreg and autoimmune diseases. Treg cells and those subpopulations were analyzed by using the human regulatory T cell staining kit and CD45RA surface marker for 42 rheumatoid arthritis (RA), 13 systemic lupus sclerosis (SLE), 7 Behcet's disease (BD), and 22 healthy controls. The proportion of Treg cells was significantly lower in RA (3.8% +/- 1.0%) (P < 0.001) and BD (3.3% +/- 0.5%) (P < 0.01) compared to healthy controls (5.0% +/- 1.3%). The proportion of aTreg cells was also significantly lower in RA (0.4% +/- 0.2%) (P = 0.008) and BD (0.3% +/- 0.1%) (P = 0.013) compared to healthy controls (0.6% +/- 0.3%). The rTreg cells showed no significant differences. The ratio of aTreg to rTreg was lower in RA patients (0.4% +/- 0.2%) than that in healthy controls (0.7% +/- 0.4%) (P = 0.002). This study suggests that the decrement of aTreg not rTreg cells contributes the decrement of total Treg cells in peripheral blood of RA and BD autoimmune diseases. Detailed analysis of Treg subpopulations would be more informative than total Treg cells in investigating mechanism of autoimmune disease.

Keyword

Regulatory T Cells; Autoimmune Diseases; Systemic Lupus Erythematosus; Rheumatoid Arthritis; Behcet Disease

MeSH Terms

Adult
Aged
Antigens, CD4/metabolism
Antigens, CD45/metabolism
Arthritis, Rheumatoid/*immunology/metabolism
Behcet Syndrome/*immunology/metabolism
Female
Forkhead Transcription Factors/metabolism
Humans
Interleukin-2 Receptor alpha Subunit/metabolism
Leukocyte Count
Lupus Erythematosus, Systemic/*immunology/metabolism
Male
Middle Aged
T-Lymphocytes, Regulatory/*cytology/immunology/metabolism
Antigens, CD4
Forkhead Transcription Factors
Interleukin-2 Receptor alpha Subunit
Antigens, CD45

Figure

  • Fig. 1 Detection of Treg cells and subpopulations by flowcytometry. (A) CD25 and FoxP3 expression in CD4+ cells. The gated (a) population was regarded as CD25highFoxP3+ Treg cells. (B) CD25 and CD45RA expression in CD4+ cells. The gated (a) population was regarded as CD4+CD25+++CD45RA- activated Treg (aTreg) cells, the (b) population as CD4+CD25++CD45RA+ resting Treg (rTreg) cells and (c) population was regarded as CD4+CD25++CD45RA- non-suppressive T cells. Treg, regulatory T cells; FoxP3, forkhead box P3; PE-Cy5, phycoerythrin-cyanin 5; PE, phycoerythrin.

  • Fig. 2 The proportion of CD3+CD4+ cells and the absolute CD4+ T cell count. (A) The proportion of CD4+ in CD3+ T cell was significantly lower in SLE group than RA, BD, or healthy controls. (B) The absolute count of the CD4+ T cells was significantly lower in SLE group than RA or healthy controls. RA, rheumatoid arthritis; BD, Behcet's disease; SLE, systemic lupus erythematosus; HC, healthy controls; Treg, regulatory T cells; aTreg, activated Treg cells; rTreg, resting Treg cells.

  • Fig. 3 Comparison of proportions of total Treg cells, aTreg and rTreg subpopulations. (A) The proportion of Treg cells was significantly lower in RA and BD than healthy controls. (B) The proportion of aTreg cells was significantly lower in RA and BD compared to healthy controls. (C) The proportions of rTreg were not different between disease groups and healthy controls. (D) RA patients showed a significantly decreased ratio of aTreg to rTreg. RA, rheumatoid arthritis; BD, Behcet's disease; SLE, systemic lupus erythematosus; HC, healthy controls; Treg, regulatory T cells; aTreg, activated Treg cells; rTreg, resting Treg cells.


Reference

1. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001. 167:1245–1253.
2. Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, Maeda M, Onodera M, Uchiyama T, Fujii S, et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol. 2004. 16:1643–1656.
3. Costantino CM, Baecher-Allan CM, Hafler DA. Human regulatory T cells and autoimmunity. Eur J Immunol. 2008. 38:921–924.
4. Cvetanovich GL, Hafler DA. Human regulatory T cells in autoimmune diseases. Curr Opin Immunol. 2010. 22:753–760.
5. Kuhn A, Beissert S, Krammer PH. CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus. Arch Dermatol Res. 2009. 301:71–81.
6. Zhang B, Zhang X, Tang F, Zhu L, Liu Y. Reduction of forkhead box P3 levels in CD4+CD25high T cells in patients with new-onset systemic lupus erythematosus. Clin Exp Immunol. 2008. 153:182–187.
7. Lyssuk EY, Torgashina AV, Soloviev SK, Nassonov EL, Bykovskaia SN. Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv Exp Med Biol. 2007. 601:113–119.
8. Kawashiri SY, Kawakami A, Okada A, Koga T, Tamai M, Yamasaki S, Nakamura H, Origuchi T, Ida H, Eguchi K. CD4+CD25highCD127low/-Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011. 38:2517–2521.
9. Sugita S, Yamada Y, Kaneko S, Horie S, Mochizuki M. Induction of regulatory T cells by infliximab in Behcet's disease. Invest Ophthalmol Vis Sci. 2011. 52:476–484.
10. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood. 2006. 108:253–261.
11. Yan B, Ye S, Chen G, Kuang M, Shen N, Chen S. Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum. 2008. 58:801–812.
12. Alvarado-Sánchez B, Hernández-Castro B, Portales-Pérez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, Cubillas-Tejeda AC, González-Amaro R. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2006. 27:110–118.
13. van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 2004. 50:2775–2785.
14. Valencia X, Lipsky PE. CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol. 2007. 3:619–626.
15. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2008. 105:19396–19401.
16. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009. 30:899–911.
17. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997. 40:1725.
18. International Study. Criteria for diagnosis of Behçet's disease. Lancet. 1990. 335:1078–1080.
19. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2010. 62:2569–2581.
20. Moon HW, Kim BH, Park CM, Hur M, Yun YM, Kim SY, Lee MH. CD4+CD25highFoxP3+ regulatory T-cells in hematologic diseases. Korean J Lab Med. 2011. 31:231–237.
21. Wouters CH, Diegenant C, Ceuppens JL, Degreef H, Stevens EA. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship. Br J Dermatol. 2004. 150:693–700.
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr